af-001 (TAH-1005)
Thyroid Cancer (Radioiodine-Refractory)
Phase 1Active (Preparing for company-sponsored trial)
Key Facts
Indication
Thyroid Cancer (Radioiodine-Refractory)
Phase
Phase 1
Status
Active (Preparing for company-sponsored trial)
Company
About Alpha Fusion
A Japanese biotech developing targeted alpha therapies using Astatine-211 for precise cancer treatment with minimal side effects.
View full company profile